Are Weight Loss Clinics Profitable After FDA's 2026 Compounding Actions?

Are weight loss clinics profitable? They can be, though the widely quoted 80% margin cites no source and 2026 changed the math. With FDA tightening on compounded GLP-1s and brand drugs sold directly to patients, profit now depends on program model and retention. A Practice Diagnostic tests both.

By Michael Madrinkian, MBA, PhD, Founder and Principal, Luminary Strategic

THE SHORT ANSWER

• No audited margin exists in public. The figures online come from vendors and carry no source. Treat them as claims.

• Margin percentage misleads here. In the example above, a fee-only program shows the highest percentage and earns the fewest dollars per patient.

• Brand prices now cap compounded prices. Patients can buy Wegovy and Zepbound directly from the manufacturers, so an all-in compounded program competes with a published number.

• FDA's actions change the risk. The compounded columns in any business plan rest on federal conditions your attorney and pharmacy need to confirm.

• Retention decides the line. In one large study, about two of three patients without diabetes stopped within a year. A clinic replaces them every month or the program shrinks.

WHERE THE 80% MARGIN COMES FROM

Search this question and you will find one number repeated: part-time weight loss programs earning about $250,000 a year at margins around 80%, and full-time clinics passing $1 million at margins above 50%. The source is Pabau, a clinic-software company, in a blog post last updated September 22, 2026, and in a downloadable ebook from the same company. Neither one cites a source for those margins. The one market figure on the blog page with a link is a total market projection from Grand View Research, which says nothing about a single clinic's profit.

Pabau may be describing real clinics. A reader has no way to check, because the page does not say which clinics, in what year, or whether "profit margin" means what is left after the owner's pay, rent, and marketing. Is owning a medical spa profitable, an earlier post in this series, shows how one practice can honestly report 3%, 12%, or 25% depending on how profit is counted. An unlabeled 80% could be any of those views, or a margin on a single line before any overhead.

We could not find an audited margin benchmark for weight loss clinics. So this post offers a method you can run against your own numbers, with a hypothetical to show how it works.

ARE WEIGHT LOSS CLINICS PROFITABLE? THREE MODELS ON THE SAME MATH

The table above is a labeled hypothetical. It describes no real clinic, and every input is an assumption for you to replace. Three models sit side by side, each measured over a four-week billing period:

All-in compounded at $399

The patient pays one price, and the practice buys the medication from a pharmacy at an assumed $130 with shipping. This model leaves about $213 per patient before fixed costs, or 53% of what the practice collects.

All-in compounded at $349

The same program, priced to match the published Wegovy pen price. Lowering the price by $50 takes about $48 from the practice after the card fee, because the medication and provider time cost the same. The practice now keeps about $165.

Brand drug plus a $149 fee

The patient buys the drug directly from the manufacturer and pays the practice a monthly fee for visits, monitoring, and coaching. The practice carries no medication cost and keeps about $101 of $149, or 68%. The patient's total rises to $498.

Read the last two rows of the table together. If the line carries $9,000 a month in fixed costs (marketing, software, a share of rent and front desk, and physician oversight), the first model covers them with 43 active patients. The fee model needs 90. The highest percentage in the table comes with the highest patient count. So are weight loss clinics profitable on these numbers? Each model can be, once it clears its own patient count.

The compounded columns show arithmetic only. They do not suggest that any compounded product is available to your practice or fits the federal conditions below. That determination belongs to your attorney and your pharmacy.

WHAT FDA DID, IN ORDER

A drug on FDA's shortage list can be compounded under conditions that do not apply once the shortage ends. These are the dated actions an owner should have in front of them, as of November 3, 2026.

Three points from FDA's April 1, 2026 statement matter most for a business plan. The statement restates conditions already in the law.

The copy standard. Under section 503A, FDA treats a compounded drug as essentially a copy of a commercially available product when it has the same active ingredient at the same, similar, or easily substitutable strength, and the commercial product can be used by the same route. FDA's example is semaglutide combined with vitamin B12.

The documented exception. The standard does not apply when a prescriber determines and documents a change that produces a significant difference for an identified individual patient. FDA also says it does not currently intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month.

Outsourcing facilities. Under section 503B, FDA states that semaglutide and tirzepatide appear on neither the bulks list nor the shortage list. In May 2026 it proposed leaving semaglutide, tirzepatide, and liraglutide off the bulks list. The comment period closed July 30, 2026. Our search of the Federal Register on November 3, 2026 found no final notice.

Marketing is its own exposure. FDA's March 2026 letters to 30 telehealth companies cited claims implying a compounded product is the same as an approved drug, and advertising under a firm's own name in a way that implies it made the product. Texas has its own advertising rule, summarized in med spa promotion ideas. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed.

HOW BRAND SELF-PAY PRICES CAP YOUR PRICE

A clinic's compounded price now sits next to a price the manufacturer publishes on its own website. As of November 3, 2026:

• Wegovy pen: $349 a month for all doses through 2.4 mg, with an introductory $199 for the first two fills for new patients through December 31, 2026.

• Wegovy pill: $149 to $299 a month, by dose.

• Zepbound KwikPen: $299 for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg, with the $449 price tied to refilling within 45 days. The savings terms end December 31, 2026.

Those prices cover the medication only. Your program sells the visits, monitoring, and coaching around it. A patient comparing options can now see what each part costs. A clinic priced at $399 all-in is charging $50 above the Wegovy pen for a program and an unapproved drug. Some patients will pay it, and others will ask why. Your staff need a truthful answer that makes no claim of equivalence.

The manufacturers can change these offers at any time. Recheck them before you set a price, and build the plan to survive a cut. Run the table with the brand price $50 lower and see which model still covers its fixed costs.

WHY RETENTION DECIDES THE LINE

The best public evidence on how long patients stay comes from a study in JAMA Network Open: 125,474 adults with overweight or obesity who started liraglutide, semaglutide, or tirzepatide between 2018 and 2023. Among those without type 2 diabetes, 64.8% had discontinued within a year. Among those who stopped, 36.3% restarted within the following year. The data come from health records and predate today's cash prices, so a self-pay clinic's experience may differ. Measure your own.

Here is what that rate does to a plan. If 64.8% of patients leave over 12 months at a steady pace, about 8.3% leave each month, and the average patient stays about 7.8 of those first 12 months. Applied to the table:

• First-year earnings per patient before fixed costs: about $1,660 for the $399 program, $1,280 for the $349 program, and $785 for the fee model.

• New patients needed each month to stay at break-even: about 3.6, 4.6, and 7.5.

Those are the two numbers to take to your marketing budget. If it costs $300 to bring in a patient who starts the program, the fee model spends more than a third of its first-year earnings on acquisition. The $399 model spends less than a fifth. Each month you extend the average stay lifts every figure, so a maintenance plan and a defined step-down visit are financial decisions as well as clinical ones, and the clinical part belongs to your prescribers.

WHAT TO MODEL BEFORE YOU ADD OR KEEP A PROGRAM

1. Your real cost per patient. Medication, shipping, labs, and provider minutes per patient per month, measured from the schedule.

2. The fee model on its own. If compounded supply became unavailable tomorrow, how many active patients would the fee model need, and do you have them?

3. Your actual attrition. Count patients active on the first of each month for a year. Use your rate in place of 8.3%.

4. Overhead the line really uses. Include the provider hours it takes from injectables or hormones. A filled schedule of low-margin visits can displace higher earners.

5. Physician oversight. Delegated prescribing runs through prescriptive authority agreements in Texas. An oversight fee belongs in fixed costs. How much to pay a medical director for a med spa covers how to think about that number.

6. Unused prepayment. If you sell packages, treat the undelivered portion as a liability until you deliver it.

Questions for your attorney

The summaries in this post are general descriptions as of November 3, 2026, and they are not legal advice. Whether and how any of them applies to your practice is a question for your healthcare attorney:

• Does any product we prescribe or plan to prescribe raise the "essentially a copy" question, and who documents a patient-specific difference?

• What should our pharmacy agreement say about the conditions it relies on and about notice if supply changes?

• Does our advertising describe a compounded product in a way FDA or the Texas Medical Board's advertising rule would question?

• Does any payment between the practice and a pharmacy, telehealth partner, or marketer raise an issue under Texas Occupations Code §102.001?

• How do our prescriptive authority agreements cover this program?

Luminary designs the cost model, the records, and the review calendar around your attorney's answers. How Luminary approaches med spa compliance.

WHAT A PROGRAM REVIEW COSTS

The Practice Diagnostic reviews a wellness or weight loss line through its finance, operations, and compliance lenses, with benchmarks adjusted for your service mix, and ranks the constraints that matter most. Three weeks, from $5,000. Owners deciding whether to restructure, add, or exit a program use the Advisory Engagement, from $15,000. Founders planning a new Texas clinic can start with Pre-Opening Advisory.

Luminary is an independent firm of medical spa consultants. Luminary takes no compensation from device makers, distributors, lenders, or software vendors.

FREQUENTLY ASKED QUESTIONS

What is a realistic profit margin for a medical weight loss clinic?

We could not find an audited public benchmark. Vendor pages quote 50% to 80% without a source or a definition of profit. Build the figure from your own cost per patient, attrition, and fixed costs, and state which kind of profit you mean.

How many patients does a GLP-1 program need to break even?

Divide the line's monthly fixed costs by what each patient leaves after direct costs. In this post's hypothetical, $9,000 in fixed costs takes 43 active patients at $213 each or 90 at $101 each.

Can a med spa still offer compounded semaglutide?

FDA describes conditions for compounding under sections 503A and 503B, and the April 2026 statement restates them. Whether a specific product and arrangement fit those conditions is a question for your healthcare attorney and pharmacy.

How long do patients stay on GLP-1 medication?

In a study of 125,474 US adults published in JAMA Network Open in 2025, 64.8% of those without type 2 diabetes stopped within a year. Some restarted later. Track your own retention, since self-pay clinics may differ.

How much does it cost to start a weight loss clinic?

Pabau's blog quotes $100,000 to $500,000 without citing a source. An existing practice adding a program has a different question: what the added staff time, oversight, software, and marketing cost each month, and how many active patients cover them.

REQUEST A SCOPING CALL

Luminary works with med spa and wellness practice owners in person across Dallas-Fort Worth and virtually nationwide. A scoping call is 30 minutes and confirms which engagement fits. Request a scoping call or call 469-894-8793.

SOURCES

• U.S. Food and Drug Administration, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize" (content current as of April 1, 2026), checked November 3, 2026: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

• U.S. Food and Drug Administration, "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs" (February 6, 2026): https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs

• U.S. Food and Drug Administration, warning letters to 30 telehealth companies (March 3, 2026): https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s

• U.S. Food and Drug Administration, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (April 30, 2026): https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list

• Federal Register, List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (91 FR 23431, May 1, 2026): https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

• Federal Register, Extension of Comment Period to July 30, 2026 (June 26, 2026): https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal

• NovoCare Pharmacy, Wegovy self-pay offer, checked November 3, 2026: https://www.novocare.com/pharmacy/wegovy/offer.html

• Eli Lilly, Zepbound coverage and savings, checked November 3, 2026: https://www.zepbound.lilly.com/coverage-savings

• Rodriguez PJ, Zhang V, Gratzl S, et al., "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity," JAMA Network Open, 2025;8(1):e2457349: https://doi.org/10.1001/jamanetworkopen.2024.57349

• Pabau, "How Weight Loss Clinics Make Money" (vendor claims, last updated September 22, 2026), checked November 3, 2026: https://pabau.com/blog/how-weight-loss-clinics-make-money/

• Pabau, weight loss ebook (vendor claims, repeats the same figures): https://pabau.com/wp-content/uploads/2026/02/weight-loss-ebook-v2.pdf

• Texas Administrative Code, Title 22, §164.3 (advertising): https://www.law.cornell.edu/regulations/texas/22-Tex-Admin-Code-SS-164-3

• Texas Occupations Code, Chapter 102: https://statutes.capitol.texas.gov/Docs/OC/htm/OC.102.htm